It’s been a turbulent year for the stalwart health and wellness retailer Walgreens Boots Alliance (NASDAQ: WBA) as the company’s shares plummeted by a staggering 60% over the past 12 months. The pressing question on investors’ minds centers around the viability of this downfall as a compelling buying opportunity or a precursor to further plummeting.
Diving into the core reasons behind Walgreens’ stock market strife and exploring potential avenues for recuperation is essential.
Challenges of Reimbursement and Ill-fated Acquisitions
Foremost among the challenges confronting Walgreens is the relentless downward pressure on drug reimbursement prices emanating from pharmacy benefit managers (PBMs). These entities act as intermediaries between drug manufacturers, health insurers, and pharmacies, driving discounts for drug firms and setting pharmacy reimbursement rates for insurers.
Walgreens, among others, has borne the brunt of a decade-long squeeze in margins due to the uncompromising stance of PBMs. As an indicator, the company’s gross margin shrank from 28.2% in fiscal year 2014 to a meager 19.5% in the most recent fiscal year, underscoring a substantial profit erosion trend.
In an ill-fated move, Walgreens ventured into a majority acquisition of VillageMD, a primary care clinics operator that failed to expand outside its core regions following the subsequent purchase of Summit Medical. Such missteps have encumbered Walgreens’ financial performance, with VillageMD defaulting on a substantial secured loan extended by Walgreens.
Image source: Getty Images.
Remedial Measures for Redemption
Walgreens recently divulged its contemplation of strategic alternatives concerning VillageMD, thereby weighing an outright sale of the ailing business unit—an action that could potentially unshackle Walgreens from a burdensome investment.
Strategically closing unprofitable store locations nationwide embodies a pivotal step for Walgreens. This undertaking promises a dual benefit: cost rationalization through reduced overheads and enhanced revenue concentration in retained store footprints. Such an approach is anticipated to bolster same-store sales and margins, facilitating profitability under a leaner operational structure.
In the long haul, Walgreens’ imperative revolves around mitigating the relentless squeeze on reimbursement rates. Collaborative engagement with PBMs and payers to institute a more equitable cost-plus drug pricing model emerges as a strategic dialogue. Sustainable alleviation of reimbursement pressures and the exploration of innovative pricing paradigms are essential for preserving the long-term viability of pharmacy operations.
Navigating the Market Landscape
From a valuation lens, Walgreens appears conspicuously undervalued, trading at a meager 5 times forward earnings based on analyst prognostications for the upcoming fiscal period. Incorporating an enterprise value-to-EBITDA metric to reflect debt obligations, Walgreens registers a modest multiple of just over 4 times.
Despite the alluring bargain basement valuation, an arduous path to recovery looms ahead for Walgreens. Critical imperatives entail divesting from VillageMD to alleviate debt burdens, streamlining store portfolios, and advocating for more favorable reimbursement structures with PBMs.
The potential for significant upside exists if Walgreens orchestrates a successful turnaround. Conversely, failure to execute remedial strategies could consign the stock to a value trap scenario.
Considering the overarching prospects, a measured investment stance is advisable, positioning for a potential resurgence while prudently managing exposure to inherent risks.
Decision Time: Investing in Walgreens Boots Alliance
Prior to delving into Walgreens Boots Alliance stock, contemplating the insights below is indispensable:
The Motley Fool Stock Advisor experts have curated a list of the top 10 stock picks anticipated to yield substantial returns, with Walgreens Boots Alliance conspicuously omitted from the selection. The featured stocks bear the potential for exponential growth in the forthcoming years.
Reflecting on historical successes, the inclusion of Nvidia in the 2005 list ushered in monumental returns for investors, illustrating the transformative power of timely investment decisions.
The Stock Advisor service heralds a roadmap to investment success, showcasing a track record that surpasses the S&P 500 returns by a manifold since its inception in 2002.
Explore the top 10 stocks for investment opportunities »
*Stock Advisor returns cited as of August 12, 2024